Regents of Univ of Minnesota

1. ADC Therapeutics America, Inc. $579,496 33 payments
2. Ucb SA $249,891 24 payments
3. GlaxoSmithKline, LLC. $249,145 14 payments
4. TESARO, Inc. $19,703 1 payment
5. Takeda Pharmaceuticals U.S.A., Inc. $12,357 5 payments
6. Mallinckrodt Hospital Products Inc. $7,988 2 payments
7. Acacia Pharma Inc $6,020 3 payments
8. Mallinckrodt Enterprises LLC $416 1 payment

1. A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3) $325,355 21 payments
2. A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $249,145 14 payments
3. A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of Ucb1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) $188,691 4 payments
4. A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma $125,086 6 payments
5. A Study to Evaluate the Safety $55,371 1 payment
6. A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS 7) $43,144 3 payments
7. Phase 3, Multicenter, Randomized, Double-Blind, PBO-Controlled Study of Efficacy, Safety, and Tolerability of Zilucoplan in Subjects with Generalized Myasthenia Gravis $39,148 7 payments
8. A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) $30,540 2 payments
9. A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant, Investigator, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of Ucb1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) $22,053 13 payments
10. A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens $19,703 1 payment

1. Other $6,020 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.